Detalhe da pesquisa
1.
A phase I/II study evaluating the pharmacokinetics, pharmacodynamics, and safety of drospirenone as an oral contraceptive in Japanese women.
J Obstet Gynaecol Res
; 50(4): 682-690, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262424
2.
The drospirenone (DRSP)-only pill: clinical implications in the daily use.
Eur J Contracept Reprod Health Care
; 28(1): 36-43, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724207
3.
The progestin-only pills drospirenone 4 mg and desogestrel 0.075 mg as an option for the management of dysmenorrhea and mastodynia.
Gynecol Endocrinol
; 38(11): 978-982, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265507
4.
Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg.
Gynecol Endocrinol
; 38(4): 333-338, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261299
5.
Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4 mg drospirenone only in a 24/4 regimen and comparison to 0.075 mg desogestrel.
Gynecol Endocrinol
; 37(12): 1121-1127, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34402728
6.
Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study.
Eur J Contracept Reprod Health Care
; 26(6): 454-461, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34348526
7.
Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime.
BMC Womens Health
; 20(1): 218, 2020 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33008401
8.
Correction to: A multicenter, double-blind, randomized trial on the bleeding profle of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg.
Arch Gynecol Obstet
; 301(6): 1593, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32328709
9.
Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature.
Eur J Contracept Reprod Health Care
; 25(3): 221-227, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32312141
10.
Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill.
Acta Obstet Gynecol Scand
; 98(12): 1549-1557, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31321765
11.
A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg.
Arch Gynecol Obstet
; 300(6): 1805-1812, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31728664
12.
In vitro evaluation of microbial adhesion to a contraceptive vaginal ring with a new polymer composition.
Eur J Contracept Reprod Health Care
; 24(3): 188-191, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30977415
13.
Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 µg per day.
Gynecol Endocrinol
; 32(9): 749-751, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27028425
14.
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
Urol Int
; 90(3): 321-8, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23258223
15.
The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese users.
Contraception
; 128: 110136, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37544572
16.
Development and Validation of an Endometriosis Diagnostic Method Based on Serum Biomarkers and Clinical Variables.
Biomolecules
; 13(7)2023 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509088
17.
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
BJU Int
; 110(11): 1721-8, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22500884
18.
Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.
J Urol
; 186(5): 1835-42, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21944083
19.
A single-arm study to evaluate the transfer of drospirenone to breast milk after reaching steady state, following oral administration of 4 mg drospirenone in healthy lactating female volunteers.
Womens Health (Lond)
; 16: 1745506520957192, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32903172
20.
Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase.
Contraception
; 101(6): 412-419, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32088174